NIAID Emerging and Re-emerging Infectious Diseases NIAID Bioinformatics Resource Centers NIAID Structural Genomic Centers Center for Structural Genomics of Infectious Disease
Seattle Structural Genomics Center for Infectious Disease

MyulA.01530.g: Enoyl-CoA hydratase EchA19

Target Characteristics

from organism: Mycobacterium ulcerans Agy99
most recent status: purified
center reference id: MyulA.01530.g
is community request: False
associated disease: Buruli, Bairnsdale ulcer
NIH risk group: 2
is select agent: False
NIH priority
pathogens category:
IIIC

Ordering Clones & Proteins

If there are materials available for this target, they will be listed below. Materials can be ordered from SSGCID using the button in the "order material" column. Clicking the button will add the material to a virtual cart. You may order multiple materials at a time at no cost to you, as this contract is funded by NIAID. When you are ready to place your order, click the "Place Order" link which will appear in the top right corner of the page after you place your first item in your cart.

Clones*

CENTER
REFERENCE ID
DOMAIN/REGION
DESCRIPTION
INFO AA
START
AA
STOP
ORDER
MATERIAL
MyulA.01530.g.A1.GE29901 Full length( MyulA.01530.g ) 1 284 GE29901
* SSGCID clones represent un-induced expression constructs which have been verified by sequencing from vector primers. Clones may contain a tag, such as N-term 6xHis. Get sequence information using the button in the "info" column.

Proteins

CENTER
REFERENCE ID
DOMAIN/REGION
DESCRIPTION
INFO AA
START
AA
STOP
ORDER
MATERIAL
MyulA.01530.g.A1.PW29767 Full length( MyulA.01530.g ) 1 284

External Resources

Resource Reference ID
OrthoMCL: OG5_169926
PATRIC ID: fig|362242.7.peg.4739
RefSeq: YP_907596.1
UniProt: A0PUV6

Enzyme & Pathway Information

Pathway Pathway ID EC Number
fatty acid beta-oxidation I FAO-PWY 4.2.1.17
L-isoleucine degradation I ILEUDEG-PWY 4.2.1.17
oleate beta-oxidation PWY0-1337 4.2.1.17
phenylacetate degradation I (aerobic) PWY0-321 4.2.1.17
benzoyl-CoA degradation I (aerobic) PWY-1361 4.2.1.17
fermentation to 2-methylbutanoate PWY-5109 4.2.1.17
fatty acid beta-oxidation II (peroxisome) PWY-5136 4.2.1.17
unsaturated, even numbered fatty acid beta-oxidation PWY-5138 4.2.1.17
superpathway of glyoxylate cycle and fatty acid degradation PWY-561 4.2.1.17
superpathway of phenylethylamine degradation PWY-6071 4.2.1.17
4-hydroxybenzoate biosynthesis III (plants) PWY-6435 4.2.1.17
fatty acid beta-oxidation VI (peroxisome) PWY66-391 4.2.1.17
pyruvate fermentation to hexanol (engineered) PWY-6863 4.2.1.17
superpathway of cholesterol degradation I (cholesterol oxidase) PWY-6928 4.2.1.17
superpathway of testosterone and androsterone degradation PWY-6937 4.2.1.17
androstenedione degradation PWY-6944 4.2.1.17
superpathway of cholesterol degradation II (cholesterol dehydrogenase) PWY-6947 4.2.1.17
methyl ketone biosynthesis (engineered) PWY-7007 4.2.1.17
4-coumarate degradation (anaerobic) PWY-7046 4.2.1.17
fatty acid salvage PWY-7094 4.2.1.17
jasmonic acid biosynthesis PWY-735 4.2.1.17
docosahexaenoate biosynthesis III (6-desaturase, mammals) PWY-7606 4.2.1.17
(8E,10E)-dodeca-8,10-dienol biosynthesis PWY-7654 4.2.1.17
Spodoptera littoralis pheromone biosynthesis PWY-7656 4.2.1.17
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate biosynthesis (6-desaturase) PWY-7726 4.2.1.17
toluene degradation to benzoyl-CoA (anaerobic) PWY-81 4.2.1.17
L-valine degradation I VALDEG-PWY 4.2.1.17

Sequences

These sequences are the native gene sequence; sequences of constructs derived from these sequences may differ due to codon optimization or other protocols. To find the specific sequence of any material you may have ordered, click on the "more" button next to the name of that material.
AA Sequence
MPDVMRKAVL VAPNTSETPA NGESGPDALV EQRGHTLIVT MNRPSRRNAL SGEMMQIMVE AWDRVDNDPD IRCCILTGAG DYFCAGMDLK AATKKPPGDS FKDGSYDPSR IDALLKGRRL KKPLIAAVEG PAIAGGTEIL QGTDIRVAAE SAKFGISEAE WSLYPMGGSA VRLVRQIPYT VACDLLLTGR HITAAEAKEM GLVGHVVPDG QALTKALEIA EIIAANGPLA VQAILRTIRE TEGMHENEAF KIDTRIGIEV FLSDDAKEGP QAFAQKRKPN FQNR

NT Sequence
ATGCCCGATG TCATGCGAAA GGCGGTGCTC GTGGCCCCGA ATACTTCCGA GACGCCAGCA AACGGGGAGT CCGGACCAGA CGCGCTGGTG GAGCAGCGCG GGCACACCCT GATCGTGACG ATGAATCGCC CGTCCCGACG TAACGCGCTT AGTGGCGAAA TGATGCAAAT CATGGTCGAG GCCTGGGATC GCGTCGACAA CGATCCCGAC ATCCGCTGCT GCATCCTGAC CGGCGCGGGC GACTACTTCT GCGCTGGGAT GGACCTCAAG GCGGCAACCA AGAAGCCGCC GGGCGACTCA TTCAAGGACG GCAGCTACGA CCCGTCGCGC ATCGACGCGC TGTTGAAGGG CCGCCGGCTG AAAAAGCCGC TGATCGCCGC CGTCGAGGGC CCCGCGATCG CCGGCGGAAC CGAGATTCTG CAAGGTACCG ACATTCGCGT CGCCGCCGAG AGCGCCAAGT TCGGCATCTC GGAGGCCGAG TGGAGCCTGT ACCCGATGGG CGGCTCGGCG GTGCGGCTGG TCCGCCAGAT CCCCTACACG GTGGCCTGCG ATCTGCTGCT GACCGGACGG CACATCACTG CCGCGGAGGC CAAGGAGATG GGGCTGGTGG GCCACGTCGT GCCCGACGGC CAGGCGCTGA CCAAGGCGCT GGAAATTGCG GAGATCATCG CGGCCAACGG GCCTCTTGCG GTCCAGGCGA TCTTGCGCAC CATCCGCGAA ACCGAGGGCA TGCACGAGAA CGAGGCGTTC AAGATCGACA CTCGAATCGG CATCGAGGTG TTCTTGTCCG ACGACGCCAA AGAAGGTCCG CAGGCGTTCG CGCAGAAGCG CAAACCCAAC TTCCAGAACC GC

© 2021 Seattle Children's Research Institute. All rights reserved.